39 results
Thumbnail

D2.282 - Impact of Polyethylene Terephthalate Microplastics on the Digestibility of Shrimp Allergen Tropomyosin

Thumbnail

D2.283 - Efficacy and safety of remibrutinib in adults with IgE-mediated peanut allergy: A Phase 2 study

Thumbnail

D2.286 - High Prevalence of Clinical Tolerance to Avoided Foods in LTP-Sensitized Patients

Thumbnail

D2.287 - Clinical characterization and predictors of diagnosis and severity in sunflower seed allergy in a pediatric population

Thumbnail

D2.275 - Distinct Transcriptomic Responses Across Intestinal Segments in Egg Allergy Murine Model

Thumbnail

D2.276 - Clinical and Immunological Differences in Shellfish Allergy

Thumbnail

D2.277 - Allergy to CHIA and Reactivity with SESAME

Thumbnail

D2.278 - Dose-response analysis of remibrutinib in oral food challenge outcomes among adults with IgE-mediated peanut allergy

Thumbnail

D2.279 - Preventive capacity of single-nut sublingual immunotherapy in Brown Norway rats

Thumbnail

D2.280 - Biphasic anaphylaxis due to psyllium (Plantago ovata) allergy, the primary component of a plant-based sausage

Thumbnail

D2.281 - Ensemble Immunoinformatic Prediction Reveals Novel Allergen Candidates in Nigella sativa Seeds and Oil

Thumbnail

D2.284 - Peanut Materials Used for Immunoassay Calibration Exhibit Distinct Allergen Profiles

Thumbnail

D2.285 - Baked egg oral Immunotherapy as an alternative in patients who failed raw egg oral immunotherapy

Thumbnail

D2.288 - Real- World Safety of Supervised Feeds: Evidence from Outpatient Clinic and Dayward Settings

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis